Polygenic Risk Score and Statin Relative Risk Reduction for Primary Prevention of Myocardial Infarction in a Real-World Population.

Autor: Oni-Orisan A; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.; Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA.; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA., Haldar T; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA., Cayabyab MAS; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA., Ranatunga DK; Kaiser Permanente Division of Research, Oakland, California, USA., Hoffmann TJ; Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA., Iribarren C; Kaiser Permanente Division of Research, Oakland, California, USA., Krauss RM; Department of Pediatrics, University of California San Francisco, Oakland, California, USA.; Department of Medicine, University of California San Francisco, Oakland, California, USA., Risch N; Institute for Human Genetics, University of California San Francisco, San Francisco, California, USA.; Kaiser Permanente Division of Research, Oakland, California, USA.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Nov; Vol. 112 (5), pp. 1070-1078. Date of Electronic Publication: 2022 Aug 24.